Brokers Issue Forecasts for Upstream Bio FY2026 Earnings

Upstream Bio, Inc. (NASDAQ:UPB) – Equities research analysts at HC Wainwright boosted their FY2026 EPS estimates for shares of Upstream Bio in a research note issued to investors on Wednesday, November 11th. HC Wainwright analyst M. Caufield now forecasts that the company will earn ($3.01) per share for the year, up from their prior estimate of ($3.09). HC Wainwright currently has a “Buy” rating and a $18.00 target price on the stock. The consensus estimate for Upstream Bio’s current full-year earnings is ($2.88) per share. HC Wainwright also issued estimates for Upstream Bio’s Q4 2026 earnings at ($0.78) EPS, FY2027 earnings at ($3.21) EPS, FY2028 earnings at ($3.07) EPS, FY2029 earnings at ($3.54) EPS and FY2030 earnings at ($3.61) EPS.

Several other brokerages have also recently issued reports on UPB. Weiss Ratings upgraded Upstream Bio from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, August 17th. Wall Street Zen downgraded Upstream Bio from a “sell” rating to a “strong sell” rating in a report on Saturday, August 15th. Truist Financial lowered their price target on Upstream Bio to $25.00 and set a “buy” rating for the company in a report on Tuesday, August 11th. Finally, JPMorgan Chase & Co. upped their price target on Upstream Bio from $8.00 to $9.00 and gave the company a “neutral” rating in a research report on Friday, August 14th. Four investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Upstream Bio presently has an average rating of “Hold” and a consensus price target of $26.67.

Upstream Bio Price Performance

Shares of Upstream Bio stock opened at $2.86 on Friday. Upstream Bio has a fifty-two week low of $2.68 and a fifty-two week high of $33.68. The business has a 50-day moving average price of $4.30 and a 200 day moving average price of $8.25.

Upstream Bio (NASDAQ:UPB) last issued its quarterly earnings results on Tuesday, November 10th. The company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.73) by ($0.02). The company had revenue of $0.40 million for the quarter, compared to the consensus estimate of $0.55 million. Upstream Bio had a negative return on equity of 57.09% and a negative net margin of 5,712.33%.

Hedge Funds Weigh In On Upstream Bio

Several institutional investors have recently made changes to their positions in the stock. BlackRock Inc. bought a new position in shares of Upstream Bio during the second quarter valued at approximately $25,973,000. SEB Asset Management AB bought a new stake in shares of Upstream Bio during the first quarter valued at about $7,906,000. Parkman Healthcare Partners LLC bought a new stake in shares of Upstream Bio during the 2nd quarter worth about $6,472,000. Hsbc Holdings PLC acquired a new stake in shares of Upstream Bio in the 1st quarter worth approximately $5,763,000. Finally, Walleye Capital LLC bought a new position in shares of Upstream Bio in the second quarter valued at approximately $3,450,000.

About Upstream Bio

Upstream Bio is a clinical-stage biopharmaceutical company developing treatments for inflammatory diseases. The company is based in Waltham, Massachusetts, and its research focuses on pathways involved in immune and inflammatory responses. Its lead product candidate, verekitug (UPB-101), is an antibody designed to block the receptor for thymic stromal lymphopoietin, a protein associated with inflammation. Upstream Bio is developing verekitug for conditions including asthma and chronic rhinosinusitis with nasal polyps.